Renault Group announced it will present its new corporate strategy, 'futuReady,' on March 10, 2026. The strategy is expected to outline the automaker's plans for electric vehicle production, digital services, and sustainability targets, positioning the company for future mobility challenges.
The announcement comes amid a series of regulatory developments from the European Medicines Agency (EMA) that, while not directly related to the automotive sector, reflect the broader EU regulatory environment impacting industries including pharmaceuticals and clinical trials. On April 9, 2026, EMA published updated FAQs for the Clinical Trial Information System (CTIS) and proposed a template for sharing documents to support regulatory reliance. Earlier, on April 8, the EMA's CHMP committee discussed patient-reported outcome measures, and on April 7, the PRAC mandated new safety wording for pharmaceutical products while also releasing a new training module for CTIS.
Renault's 'futuReady' strategy will be closely watched by investors, industry analysts, and EU policymakers as it signals the company's commitment to the EU's Green Deal objectives and the transition to zero-emission mobility. The strategy is expected to address key trade-offs between innovation and tradition, as well as economic growth versus environmental protection, as the automotive industry navigates regulatory pressures and market shifts.
← Atlas › News › Transport & Infrastructure